Todos sent out a proxy asking shareholders to approve a reverse split to try to get on NASDAQ and approve the exercise of the option to acquire 100% of Breakthrough Diagnostics.
"The Company believes that the LymPro Test is positioned as potentially the first diagnostic blood test for Alzheimer’s disease. The LymPro Test is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. Scientists believe that certain diseases, most notably Alzheimer’s disease, may be the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons which then leads to apoptosis. LymPro Test uses peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain. The LymPro Test focuses on measuring immune markers that are directly linked to the cell proliferation processes and expands our understanding of how the body’s immune system responds to disease. The Company believes that the LymPro Test may use the body’s immune system response to diagnose early and monitor the progression of Alzheimer’s disease, which has the potential to be an invaluable tool for pharmaceutical companies’ development of novel treatments for Alzheimer’s.
The LymPro Test is in-licensed from the Leipzig University in Germany from the work of Dr. Thomas Arendt, a pioneer in Alzheimer’s research. At AAIC in 2015, Amarantus reported full data on a clinical trial it conducted in the United States showing a strong correlation between LymPro and an ultimate Alzheimer’s diagnosis. The feedback Amarantus received from large pharmaceutical companies was to obtain correlation data between LymPro and amyloid and/or tau. In 2016, Dr. Arendt initiated a clinical study to measure the correlation between LymPro and amyloid/tau. Breakthrough has engaged Dr. Michael Ropacki, an expert in the field of pharmaceutical diagnostic development, to serve as Chief Medical Advisor for Breakthrough. We expect significant renewed interest in the LymPro story based on this new data.
Acquiring 100% ownership of Breakthrough and its License from the University of Leipzig will strengthen the Company’s knowledge in its core field of activities and enable the Company to expand into the field of diagnostic testing for Alzheimer’s disease.
In addition, the Company believes that this transaction will establish Amarantus as a committed long-term strategic investor in the Company. Amarantus is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. More specifically, Amarantus has assigned its license to the Lympro Test to Breakthrough and will play a pivotal role in bringing this potentially disruptive technology to the diagnostic marketplace. The Company believes that engaging with a strategic investor like Amarantus that has a serious interest in the long-term success of the Company advantages all shareholders."
"The Company believes that the LymPro Test is positioned as potentially the first diagnostic blood test for Alzheimer’s disease. The LymPro Test is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. Scientists believe that certain diseases, most notably Alzheimer’s disease, may be the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons which then leads to apoptosis. LymPro Test uses peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain. The LymPro Test focuses on measuring immune markers that are directly linked to the cell proliferation processes and expands our understanding of how the body’s immune system responds to disease. The Company believes that the LymPro Test may use the body’s immune system response to diagnose early and monitor the progression of Alzheimer’s disease, which has the potential to be an invaluable tool for pharmaceutical companies’ development of novel treatments for Alzheimer’s.
The LymPro Test is in-licensed from the Leipzig University in Germany from the work of Dr. Thomas Arendt, a pioneer in Alzheimer’s research. At AAIC in 2015, Amarantus reported full data on a clinical trial it conducted in the United States showing a strong correlation between LymPro and an ultimate Alzheimer’s diagnosis. The feedback Amarantus received from large pharmaceutical companies was to obtain correlation data between LymPro and amyloid and/or tau. In 2016, Dr. Arendt initiated a clinical study to measure the correlation between LymPro and amyloid/tau. Breakthrough has engaged Dr. Michael Ropacki, an expert in the field of pharmaceutical diagnostic development, to serve as Chief Medical Advisor for Breakthrough. We expect significant renewed interest in the LymPro story based on this new data.
Acquiring 100% ownership of Breakthrough and its License from the University of Leipzig will strengthen the Company’s knowledge in its core field of activities and enable the Company to expand into the field of diagnostic testing for Alzheimer’s disease.
In addition, the Company believes that this transaction will establish Amarantus as a committed long-term strategic investor in the Company. Amarantus is a publicly traded biotechnology company focused on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. More specifically, Amarantus has assigned its license to the Lympro Test to Breakthrough and will play a pivotal role in bringing this potentially disruptive technology to the diagnostic marketplace. The Company believes that engaging with a strategic investor like Amarantus that has a serious interest in the long-term success of the Company advantages all shareholders."
5
